A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
NCT ID: NCT00002406
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
350 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Arm 1: Indinavir (800 mg, q8h) plus two pre-existing NRTIs. Arm 2: Indinavir (1,200 mg, q12h) plus two pre-existing NRTIs. Plasma viral RNA will be measured every 4 weeks for the duration of the 24-week study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indinavir sulfate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented HIV-1 seropositive status.
* CD4 count greater than 100 cells/mm3.
* Parental consent for patients under 18.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1917 Research Clinic
Birmingham, Alabama, United States
Kaiser Permanente / Infectious Disease
Los Angeles, California, United States
Tower ID Med Associates
Los Angeles, California, United States
Ctr for AIDS Research / Education and Service (CARES)
Sacramento, California, United States
San Francisco Gen Hosp / UCSF AIDS Program
San Francisco, California, United States
HIV Clinical Research
Fort Lauderdale, Florida, United States
Univ of Miami School of Medicine
Miami, Florida, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
Ponce de Leon Ctr
Atlanta, Georgia, United States
Northwestern Univ Med School
Chicago, Illinois, United States
Rush Presbyterian St Lukes Med Ctr
Chicago, Illinois, United States
Natl Naval Med Ctr / Special Immunology Clinic
Bethesda, Maryland, United States
Brigham and Women's Hosp
Boston, Massachusetts, United States
Boston Med Ctr / Clinical Research Office
Boston, Massachusetts, United States
Univ Health Ctr 7D
Detroit, Michigan, United States
Kansas City Free Health Clinic
Kansas City, Missouri, United States
Education & Research Building
Camden, New Jersey, United States
Garden State Infectious Diseases / E I P Kennedy Health Sys
Voorhees Township, New Jersey, United States
Albany Med College / Div of HIV Medicine
Albany, New York, United States
SUNY / Health Science Ctr at Brooklyn
Brooklyn, New York, United States
New York Hosp of Queens / AIDS Ctr
Flushing, New York, United States
CRIA
New York, New York, United States
St Vincents Hosp and Med Ctr / Div of HIV Med
New York, New York, United States
Anderson Clinical Research
New York, New York, United States
Akron City Hospital
Akron, Ohio, United States
Thomas Jefferson Univ
Philadelphia, Pennsylvania, United States
Anderson Clinical Research
Pittsburgh, Pennsylvania, United States
Houston Clinical Research Network / Southhampton Med Group
Houston, Texas, United States
Univ of Utah School Of Medicine / Div of Infec Disease
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-0639
Identifier Type: -
Identifier Source: secondary_id
246P
Identifier Type: -
Identifier Source: org_study_id